Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 29.63 as of 2026-10-06T22:22:22.007Z.
Consensus retrieved: 2026-10-06T13:08:06.201Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:22:22.007Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6406fd2442714d9367626958f52801bc159ff12de6dbf73702a58fff4834c07a
Forward PE Ratio (29.63) = Dated Quote Price ($7.11) / Consensus Forward EPS ($0.24)
FORWARD PE RATIO
29.63
SECTOR MEDIAN · HEALTHCARE
19.79
median of 190 covered companies
CURRENT VS SECTOR MEDIAN
+49.76%
vs the sector median at left
The Joint Corp.
Market Cap
$101.36M
Forward PE Ratio
29.63
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| The Joint Corp. (JYNT) | $101.36M | 29.63 |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.75M | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $99.62M | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $103.14M | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.26M | 5.07 |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $97.94M | N/A |
| PolyPid Ltd. (PYPD)vs › | $97.90M | N/A |
| Korro Bio, Inc. (KRRO)vs › | $97.14M | N/A |
| Immunic, Inc. (IMUX)vs › | $106.52M | N/A |
Trailing P/E
26.8
reported TTM EPS
Forward P/E
29.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.24 implies -11.1% EPS decline vs the reported trailing $0.27.
At the dated quote price of $7.11, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.24 | $0.23 – $0.25 | 1 | 29.6x |
| 2027-12-31 | $0.39 | $0.33 – $0.45 | 2 | 18.1x |
| 2028-12-31 | $0.30 | $0.29 – $0.31 | 1 | 23.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
